Abstract
The synthesis of a novel antithrombotic consisting of a heparin pentasaccharide conjugated to the active site inhibitor N-(2-naphtalenesulfonyl)-glycyl-(D)-4-aminophenyl-alanyl-piperidin e (NAPAP) (i.e. compound I) is reported. This conjugate shows a unique pharmacological profile both in vitro and in vivo having direct anti-thrombin and ATIII-mediated anti-Xa activity. Furthermore, conjugate I has a prolonged in vivo half-life compared to NAPAP (1.5 h vs 9 min.).
MeSH terms
-
Animals
-
Antithrombins / chemical synthesis*
-
Antithrombins / pharmacology*
-
Carbohydrate Sequence
-
Dipeptides / chemistry*
-
Drug Design
-
Factor Xa Inhibitors
-
Half-Life
-
Heparin / chemistry
-
Inhibitory Concentration 50
-
Magnetic Resonance Spectroscopy
-
Mass Spectrometry
-
Molecular Sequence Data
-
Oligosaccharides / chemical synthesis*
-
Piperidines / chemistry*
-
Rats
-
Solubility
-
Thrombin / antagonists & inhibitors
Substances
-
Antithrombins
-
Dipeptides
-
Factor Xa Inhibitors
-
Oligosaccharides
-
Piperidines
-
N(alpha)-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide
-
Heparin
-
Thrombin